Supplementary Table 1. Exclusion criteria.

1. Requires long-term oral anticoagulation therapy for any indication other than atrial fibrillation 2. Contraindicated for or allergic to aspirin, clopidogrel, warfarin or novel oral anticoagulant (NOAC) use 3. History of surgical atrial septal defect (ASD) repair or has an ASD closure device implanted 4. History of surgical patent foramen ovale (PFO) repair or has a PFO closure device implanted 5. Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would require transfusion)	Clinical exclusion criteria		
fibrillation 2. Contraindicated for or allergic to aspirin, clopidogrel, warfarin or novel oral anticoagulant (NOAC) use 3. History of surgical atrial septal defect (ASD) repair or has an ASD closure device implanted 4. History of surgical patent foramen ovale (PFO) repair or has a PFO closure device implanted 5. Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would			
 Contraindicated for or allergic to aspirin, clopidogrel, warfarin or novel oral anticoagulant (NOAC) use History of surgical atrial septal defect (ASD) repair or has an ASD closure device implanted History of surgical patent foramen ovale (PFO) repair or has a PFO closure device implanted Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure Myocardial infarction (MI) within 90 days prior to implant New York Heart Association Class IV congestive heart failure Left ventricular ejection fraction (LVEF) <30% Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation Left atrial appendage is obliterated or surgically ligated Resting heart rate >110 bpm Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would<th>1.</th><th>Requires long-term oral anticoagulation therapy for any indication other than atrial</th>	1.	Requires long-term oral anticoagulation therapy for any indication other than atrial	
(NOAC) use 3. History of surgical atrial septal defect (ASD) repair or has an ASD closure device implanted 4. History of surgical patent foramen ovale (PFO) repair or has a PFO closure device implanted 5. Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thromboeytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		fibrillation	
 History of surgical atrial septal defect (ASD) repair or has an ASD closure device implanted History of surgical patent foramen ovale (PFO) repair or has a PFO closure device implanted Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure Myocardial infarction (MI) within 90 days prior to implant New York Heart Association Class IV congestive heart failure Left ventricular ejection fraction (LVEF) <30% Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation Left atrial appendage is obliterated or surgically ligated Resting heart rate >110 bpm Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	2.	Contraindicated for or allergic to aspirin, clopidogrel, warfarin or novel oral anticoagulant	
 implanted 4. History of surgical patent foramen ovale (PFO) repair or has a PFO closure device implanted 5. Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 		(NOAC) use	
 History of surgical patent foramen ovale (PFO) repair or has a PFO closure device implanted Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure Myocardial infarction (MI) within 90 days prior to implant New York Heart Association Class IV congestive heart failure Left ventricular ejection fraction (LVEF) <30% Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation Left atrial appendage is obliterated or surgically ligated Resting heart rate >110 bpm Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	3.	History of surgical atrial septal defect (ASD) repair or has an ASD closure device	
implanted 5. Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		implanted	
 5. Implanted with a mechanical heart valve prosthesis requiring long-term oral anticoagulation 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	4.	History of surgical patent foramen ovale (PFO) repair or has a PFO closure device	
anticoagulation 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		implanted	
 6. Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	5.	Implanted with a mechanical heart valve prosthesis requiring long-term oral	
accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or subject has active infection or bleeding disorder) 7. Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure 8. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		anticoagulation	
 subject has active infection or bleeding disorder) Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure Myocardial infarction (MI) within 90 days prior to implant New York Heart Association Class IV congestive heart failure Left ventricular ejection fraction (LVEF) <30% Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation Left atrial appendage is obliterated or surgically ligated Resting heart rate >110 bpm Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	6.	Has any contraindications for a percutaneous catheterisation procedure (e.g., unable to	
 Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure Myocardial infarction (MI) within 90 days prior to implant New York Heart Association Class IV congestive heart failure Left ventricular ejection fraction (LVEF) <30% Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation Left atrial appendage is obliterated or surgically ligated Resting heart rate >110 bpm Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 		accommodate transoesophageal echocardiogram [TEE/TOE] probe or required catheters, or	
 Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to implant, or intervention or surgery is planned within 60 days after implant procedure Myocardial infarction (MI) within 90 days prior to implant New York Heart Association Class IV congestive heart failure Left ventricular ejection fraction (LVEF) <30% Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation Left atrial appendage is obliterated or surgically ligated Resting heart rate >110 bpm Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 		subject has active infection or bleeding disorder)	
 implant, or intervention or surgery is planned within 60 days after implant procedure 9. Myocardial infarction (MI) within 90 days prior to implant 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	7.	Stroke or transient ischaemic attack (TIA) within 90 days prior to implant procedure	
 Myocardial infarction (MI) within 90 days prior to implant New York Heart Association Class IV congestive heart failure Left ventricular ejection fraction (LVEF) <30% Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation Left atrial appendage is obliterated or surgically ligated Resting heart rate >110 bpm Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	8.	Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to	
 10. New York Heart Association Class IV congestive heart failure 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 		implant, or intervention or surgery is planned within 60 days after implant procedure	
 11. Left ventricular ejection fraction (LVEF) <30% 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	9.	Myocardial infarction (MI) within 90 days prior to implant	
 12. Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	10.	New York Heart Association Class IV congestive heart failure	
ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would	11.	Left ventricular ejection fraction (LVEF) <30%	
TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would	12.	Symptomatic carotid artery disease (defined as >50% reduced diameter with symptoms of	
subject is eligible if there is >50% reduced diameter 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric	
 13. Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 		TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the	
trauma, recent major surgical procedures) 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		subject is eligible if there is >50% reduced diameter	
 14. History of idiopathic or recurrent venous thromboembolism requiring long-term oral anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	13.	Reversible cause of AF (i.e., secondary thyroid disorders, acute alcohol intoxication,	
anticoagulation 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		trauma, recent major surgical procedures)	
 15. Left atrial appendage is obliterated or surgically ligated 16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would 	14.	History of idiopathic or recurrent venous thromboembolism requiring long-term oral	
16. Resting heart rate >110 bpm 17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would		anticoagulation	
17. Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would	15.	Left atrial appendage is obliterated or surgically ligated	
concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would	16.	Resting heart rate >110 bpm	
	17.	Thrombocytopaenia (defined as <70,000 platelets/mm³) or anaemia with haemoglobin	
require transfusion)		concentration of <10 g/dl (i.e., anaemia as determined by the investigator which would	
		require transfusion)	

- 18. Actively enrolled or plans to enrol in a concurrent clinical study in which the active treatment arm may confound the results of this trial
- 19. Active endocarditis or other infection producing bacteraemia
- 20. Subject has a known malignancy or other illness where life expectancy is less than 2 years
- 21. Impaired renal function with eGFR <40 ml/min/1.73 m²
- 22. Patient with more than mild hepatic failure as per Munich consensus document

Cardiac imaging exclusion criteria

- 1. Intracardiac thrombus including LAA visualised by echocardiographic imaging
- 2. Existing circumferential pericardial effusion >2 mm
- 3. Significant mitral valve stenosis (i.e., mitral valve area <1.5 cm²)
- 4. High-risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (atrial septal excursion >15 mm; excursion defined as maximal protrusion of the ASA beyond the plane of the atrial septum during cardiac cycle) or large shunt (substantial passage of bubbles, i.e., >20, within 3 cardiac cycles from appearing in the right atrium)
- 5. Complex atheroma with mobile plaque of the descending aorta and/or aortic arch
- 6. Cardiac tumour
- 7. LAA anatomy cannot accommodate an Omega device (as per IFU)
- 8. Placement of the device would interfere with any intracardiac or intravascular structure